Syndexa Pharmaceuticals Corporation and ChemDiv Announce Discovery Collaboration

ChemDiv, Inc. and Syndexa Pharmaceuticals Corporation have announced the signing of a collaborative discovery research agreement. Under the terms of the agreement, ChemDiv will discover small molecule ligands for biotargets nominated by Syndexa. Financial terms of the collaboration were not disclosed.

"We are very excited to deploy our discovery resources in this collaboration with Syndexa," said Dr. Ilya Okun, VP of Biology & CTO at ChemDiv, Inc. "ChemDiv's flexible service capabilities emphasize delivery of rapid, high-value results for our partners' drug discovery programs. We are able to realize that goal through the creative integration of the chemistry and biology components of our Discovery outsource™ platform."

"We are extremely pleased to be working with ChemDiv, a drug discovery partner with a strong track record. The collaboration will provide us with access to high quality screening capabilities and compound library resources. We anticipate that this project will accomplish our goal of discovering promising drug leads to enhance our R&D pipeline," said Teo Uysal, President and CEO, Syndexa Pharmaceuticals.